„NAD+ is the most commonly used abbreviation for nicotinamide adenine dinucleotide, but the full chemical name provides useful information about the structure and composition of this molecule. Understanding the individual parts of the name helps to explain what NAD+ is made of, how it differs from the closely related molecule NADP+, and why the biologically active form β-NAD+ is sometimes specified in scientific literature.
This article explains the chemistry of nicotinamide adenine dinucleotide, clarifies the most commonly used terminology, and discusses differences that may cause misunderstandings in scientific, commercial or translated materials. The article also explains whether nicotinamide adenine dinucleotide and products sold as „NAD+ supplements” are the same thing and what to look out for when evaluating them.
What Does Nicotinamide Adenine Dinucleotide Mean?
Each part of the name nicotinamide adenine dinucleotide describes an essential structural feature of NAD+.
Nicotinamide is the amide form of vitamin B3, also known as niacin. In the NAD+ molecule, the nicotinamide moiety acts as a chemically reactive fragment involved in electron transfer during oxidation and reduction reactions. [1]
Adenine is a nitrogenous base also found in DNA and RNA. In NAD+, adenine is linked to a ribose sugar, forming an adenosine-related structural element.
Dinucleotide means that NAD+ consists of two nucleotide units joined together. A nucleotide usually contains a nitrogenous base, a five-carbon sugar such as ribose, and one or more phosphate groups. NAD+ contains a nicotinamide–ribose–phosphate unit and an adenine–ribose–phosphate unit joined together via the phosphate groups. [1,2]
Simply put, nicotinamide adenine dinucleotide consists of two connected nucleotide fragments: one containing nicotinamide and the other containing adenine. Their connection via phosphate groups forms the characteristic NAD+ dinucleotide structure. This molecular organisation enables NAD+ to participate efficiently in electron transfer reactions catalysed by numerous enzymes throughout the cell. [2]
Molecular Structure of NAD+: Adenine, Ribose and Phosphate
The molecular structure of NAD+ becomes easier to understand when its main components are considered separately.
Two ribose molecules. NAD+ contains two molecules of ribose, a five-carbon sugar that forms part of the structural backbone connecting the nitrogenous bases to the phosphate groups. Ribose is also the sugar found in RNA.
Two phosphate groups. The two nucleotide parts of NAD+ are linked via their phosphate groups, forming a pyrophosphate bond at the centre of the molecule. This linkage influences the chemical and structural properties of NAD+.
Two nitrogenous ring structures. Adenine is located at one end of the molecule, whilst the nicotinamide ring is at the other. Adenine is also found in such biologically important molecules as ATP and nucleic acids, whereas nicotinamide is derived from vitamin B3.
The nicotinamide ring is of particular importance for the role of NAD+ in redox reactions. When NAD+ accepts electrons, the nicotinamide moiety accepts a hydride equivalent, converting the oxidised form of NAD+ into the reduced form NADH. [1]
This molecular organisation also explains why NAD+ metabolism is closely linked to both vitamin and nucleotide metabolism. Cells synthesise and salvage NAD+ using adenine-containing nucleotide components and nicotinamide precursors derived from vitamin B3. Special biosynthesis and salvage pathways constantly produce, consume and regenerate NAD+ according to the cell's needs. [2,7]
NAD+ and NADP+: What Does the Letter „P” Stand For?
NAD+ has a closely related molecule known as NADP+, or nicotinamide adenine dinucleotide phosphate. Structurally, NADP+ differs from NAD+ primarily by the presence of an additional phosphate group at the 2′ position of the ribose belonging to the adenine-containing part of the molecule. [5,6]
Although the structural difference is relatively small, it enables cells to maintain the NAD+/NADH and NADP+/NADPH pools as functionally distinct redox systems. This separation is essential because the two pairs of coenzymes participate predominantly in different types of cellular reactions.
NAD+/NADH is widely utilised in catabolic metabolism, during which nutrients are broken down to release energy. The most important examples include glycolysis and the citric acid cycle. The NADH generated in these reactions can transfer electrons to the mitochondrial respiratory chain, supporting ATP production. [1,2]
In turn, NADP+/NADPH is strongly associated with anabolic reactions involved in biosynthesis, including the production of fatty acids and cholesterol. NADPH also provides reducing power for major antioxidant systems, including glutathione- and thioredoxin-dependent pathways, which are involved in the control of reactive oxygen species. [2]
The conversion of NAD+ to NADP+ is catalysed by NAD kinase. Cytoplasmic NADK and mitochondrial NADK2/MNADK transfer a phosphate group from ATP to NAD+. [5,6] Studies indicate that this process constitutes an essential point of metabolic regulation. For instance, in experimental studies, the activity of mitochondrial NADK2 has been linked to susceptibility to hepatic lipid accumulation in animal models, suggesting that the regulation of NADP+ production can influence tissue metabolism in a manner extending beyond individual biochemical reactions. [6]
Another term that can cause misunderstanding is NADPH oxidase, usually abbreviated as NOX. NADPH oxidases are enzyme complexes, not forms of NAD+. They consume NADPH to purposefully generate reactive oxygen species. This activity is particularly important in immune defence, where the controlled production of reactive oxygen species participates in the antimicrobial response.
This demonstrates the diverse functions of NADPH: some pathways utilise its reducing power to counteract oxidative stress, whilst others exploit this same reducing capacity to deliberately generate reactive oxygen species for specific physiological functions.
What is Nicotinamide Adenine Dinucleotide (β-NAD+)?
In the scientific and commercial literature, NAD+ is sometimes referred to as beta-nicotinamide adenine dinucleotide or beta-NAD+. The beta designation does not describe a completely different coenzyme. It specifies the stereochemical configuration of naturally occurring NAD+.
The nicotinamide part of NAD+ is linked to ribose by a glycosidic bond. Theoretically, this linkage can exist in different spatial configurations designated as alpha (α) and beta (β).
The naturally occurring form recognised and utilised by biological enzyme systems is the beta configuration. Therefore, β-NAD+ is the biologically significant form present in living cells, whereas the alpha configuration is not typically utilised by human NAD+-dependent enzymes. In most biological literature, the terms „NAD+” and „β-NAD+” therefore refer to the same physiologically relevant molecule. The beta designation appears more frequently when precise chemical identification, reagent purity, or analytical precision is of particular importance. [10]
NAD+ is also not restricted solely to the intracellular environment. Research indicates that $\beta$-NAD+ can be released into the extracellular space, inter alia under conditions of cellular stress or injury. Extracellular NAD+ is also being studied as a signalling molecule in tissues such as the digestive tract and the nervous system, where it can interact with cell-surface signalling pathways associated with, among other things, inflammation and smooth muscle regulation. [10,11]
These extracellular functions are still much less well characterised than the well-established intracellular roles of NAD+ in energy metabolism and enzyme activity.
Why do researchers use both „NAD+” and „nicotinamide adenine dinucleotide”?
In scientific publications, the abbreviation NAD+, the full name nicotinamide adenine dinucleotide, and the chemically more precise term β-nicotinamide adenine dinucleotide are often used interchangeably. The choice usually depends on the context rather than any difference in the molecule itself.
In experimental methods, researchers may use the full chemical name when identifying a specific reagent. This is of particular importance in analytical chemistry, mass spectrometry, biochemical assays and reagent ordering, where NAD+ must be clearly distinguished from compounds such as NADH, NADP+, NADPH or synthetic NAD analogues. [8]
Precise terminology is also important when comparing NAD+ measurements between laboratories. NAD+ and related metabolites can be quantified using various analytical techniques, such as enzymatic cycling assays, liquid chromatography-tandem mass spectrometry, and methods based on nuclear magnetic resonance. These methods do not always yield identical results.
A 2023 meta-analysis revealed significant variability in reported NAD(P)(H) concentrations depending on the analytical method used. This highlights the importance of clearly specifying both the measured molecule and the method used for its quantification when comparing results from different studies. [8]
In abstracts, discussions, titles, and general scientific texts, the shorter term „NAD+” is used more frequently because its meaning is widely understood.
In most educational and general scientific materials, NAD+ and nicotinamide adenine dinucleotide refer to the same molecule.
Is Nicotinamide Adenine Dinucleotide the Same as NAD+ Supplement?
The distinction between NAD+ itself and the products sold as „NAD+ supplements” is significant.
Nicotinamide adenine dinucleotide is a specific molecule. However, the product referred to as an NAD+ supplement does not necessarily have to contain intact NAD+. Many products contain NAD+ precursors instead, which are smaller molecules that can enter the NAD+ biosynthesis pathways in the body.
Two intensively studied precursors are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). In human clinical trials, increases in NAD+-related parameters in the blood have been observed following oral supplementation with these precursors. [12–14]
One of the reasons for the high level of interest in precursors is the fact that intact NAD+ is a relatively large and charged molecule, which can hinder its conventional oral absorption. For this reason, oral products containing NR or NMN have become more common than preparations based solely on intact NAD+.
NAD+ is also offered in some places as an intravenous infusion or injection, which allows the digestive tract to be bypassed. However, the evidence base for these routes of administration is less extensive than the literature concerning oral NAD+ precursors.
In a retrospective analysis comparing intravenous NAD+ with intravenous nicotinamide riboside, more gastrointestinal and cardiac symptoms were reported in the NAD+ group. [16] Because this was not a randomised controlled comparison, the results should be interpreted with caution, and definitive conclusions regarding differences in safety between these interventions cannot be drawn from them.
Human studies on oral NR and NMN have generally indicated acceptable short-term tolerance over periods ranging from a few weeks to about one year. Reported adverse effects were mostly mild and included, among others, headache, nausea, fatigue, and gastrointestinal discomfort. [15]
Nevertheless, the available clinical literature still has several significant limitations. The number of participants in many studies concerning specific health outcomes remains relatively small, and long-term safety data are still insufficient for a full assessment of the effects of prolonged supplementation across various populations. [15]
Pharmacokinetic and supplementation studies have also analysed how NAD+-related biomarkers change over time. Some results indicate that circulating levels of NAD+ indicators may increase during repeated precursor supplementation and, after a certain time, reach a relatively stable level. [17] However, the response may vary depending on the type of precursor, the dose, the studied population, the analytical method and the biological compartment analysed.
Therefore, when evaluating a product described as an „NAD+ supplement”, its actual composition should be checked. Depending on the formulation, the product may contain intact NAD+, NR, NMN, niacin, nicotinamide, or combinations of several NAD+-related compounds. These substances are chemically and biologically related, but they should not be automatically treated as equivalent, as the quantity and quality of clinical data vary between them.
Key NAD+ Related Terms in Various Languages
Terminology regarding NAD+ differs between languages, even though the molecules themselves remain chemically identical.
| English | German | Spanish | French | Polish |
|---|---|---|---|---|
| Nicotinamide adenine dinucleotide | Nicotinamide adenine dinucleotide | Nicotinamide adenine dinucleotide | Nicotinamide adenine dinucleotide | Nicotinamide adenine dinucleotide |
| NAD+ | NAD+ | NAD+ | NAD+ | NAD+ |
| Nicotinamide adenine dinucleotide phosphate (NADP+) | nicotinamide adenine dinucleotide phosphate | Nicotinamide adenine dinucleotide phosphate | Nicotinamide adenine dinucleotide phosphate | Nicotinamide adenine dinucleotide phosphate |
| Coenzyme | Coenzyme | Coenzyme | Coenzyme | Coenzyme |
These terms describe the same chemical compounds discussed throughout the article. The nomenclature varies depending on the language and naming conventions, but the molecular structures remain the same.
Limitations of Current Evidence
The fundamental structural and biochemical properties of NAD+, NADP+, NADH and NADPH are well established by decades of biochemical research. However, some newer areas of NAD+ biology are still being intensively investigated. These include, amongst other things, extracellular β-NAD+ signalling and tissue-specific regulation of NAD kinase pathways, for which some of the available evidence still comes from cellular and animal models. [6,10,11]
Another limitation is the NAD+ measurements themselves. Different analytical techniques can lead to significantly different estimates of NAD+ and related metabolites, making it difficult to directly compare absolute values between studies. [8]
Evidence comparing different ways of increasing NAD+ is also incomplete. In particular, direct data on the safety and pharmacokinetics of oral NAD+ precursors compared with intravenous NAD+ are limited, and available retrospective data should not be considered equivalent to evidence from randomised controlled trials. [16]
Finally, although NR and NMN have been studied in human clinical trials, long-term data regarding their safety and clinical effects remain limited. [15] Demonstrating an increase in NAD+-related biomarkers must also be distinguished from demonstrating a significant improvement in a specific health outcome.
Disclaimer
This article is for educational and scientific-information purposes only and should not be construed as medical advice, a diagnosis, a treatment recommendation, or a claim regarding the prevention or treatment of diseases. NAD+ is an endogenous coenzyme, whereas NAD+-related products may contain various compounds, including nicotinamide riboside, nicotinamide mononucleotide, nicotinamide, niacin, or other formulations. Therefore, the evidence regarding these compounds should be evaluated individually, without assuming that the results for one NAD+-related intervention apply to all others.
The discussed scientific evidence includes well-established biochemical studies, preclinical research, and clinical trials involving humans of varying sample sizes and durations. Although several NAD+ precursors have been evaluated in humans, evidence regarding long-term use and many of the proposed health effects remains incomplete. Intravenous and injectable NAD+ interventions also have a different and more limited evidence base than the more commonly studied oral precursors.
References
- Yoshino, J., Baur, J. A., & Imai, S. (2018). NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513–528. https://doi.org/10.1016/j.cmet.2017.11.002
- Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119–141. https://doi.org/10.1038/s41580-020-00313-x
- Rajman, L., Chwalek, K., & Sinclair, D. A. (2018). Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metabolism, 27(3), 529–547. https://doi.org/10.1016/j.cmet.2018.02.011
- Girardi, E., et al. (2020). Epistasis-driven identification of SLC25A51 as a regulator of human mitochondrial NAD import. Nature Communications, 11, 6145. https://pubmed.ncbi.nlm.nih.gov/33262325/
- Li, B.-B., et al. (2018). NAD kinases: metabolic targets controlling redox co-enzymes and reducing power partitioning in plant stress and development. Frontiers in Plant Science, 9, 379. https://pubmed.ncbi.nlm.nih.gov/29662499/
- Zhang, M., et al. (2018). Mitochondrial NADK/MNADK deficiency exacerbates diet-induced hepatic steatosis. Gastroenterology. https://pubmed.ncbi.nlm.nih.gov/28923496/
- Liu, L., et al. (2018). Quantitative analysis of NAD synthesis-breakdown fluxes. Cell Metabolism, 27(5), 1067–1080. https://pubmed.ncbi.nlm.nih.gov/29685734/
- Azouaoui, D., et al. (2023). Meta-analysis of methods used to quantify NAD(P)(H): high inter-method variability. Scientific Reports, 13, 3197. https://pubmed.ncbi.nlm.nih.gov/36774401/
- Camacho-Pereira, J., et al. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through a SIRT3-dependent mechanism. Cell Metabolism, 23(6), 1127–1139. https://pubmed.ncbi.nlm.nih.gov/27304511/
- Durnin, L., Kurahashi, M., Sanders, K. M., & Mutafova-Yambolieva, V. N. (2020). Extracellular metabolism of the enteric inhibitory neurotransmitter β-nicotinamide adenine dinucleotide (β-NAD) in the murine colon. Journal of Physiology, 598(20), 4509–4521. https://pubmed.ncbi.nlm.nih.gov/32735345/
- Bu, F., et al. (2023). Damage-released extracellular NAD activates intestinal T cells via P2X7R. Cellular Immunology. https://pubmed.ncbi.nlm.nih.gov/36746070/
- Christen, S., et al. (2026). NR and NMN comparably increase circulatory NAD+; gut microbiota converts NMN/NR to NA via the Preiss-Handler pathway. Nature Metabolism. https://pubmed.ncbi.nlm.nih.gov/41540253/
- Conze, D., Brenner, C., & Kruger, C. L. (2019). Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomised, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports, 9, 9772. https://pubmed.ncbi.nlm.nih.gov/31278280/
- Dellinger, R. W., et al. (2017). Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomised, double-blind, placebo-controlled study. NPJ Aging and Mechanisms of Disease, 3, 17. https://pubmed.ncbi.nlm.nih.gov/29184669/
- Freeberg, K. A., et al. (2023). Assessing the effects of nicotinamide riboside/nicotinamide mononucleotide supplementation: a comprehensive review. Journal of Gerontology: Series A. https://pubmed.ncbi.nlm.nih.gov/37068054/
- Reyna, S. M., et al. (2026). Retrospective comparison of intravenous NAD+ and intravenous nicotinamide riboside administration and associated adverse events. Frontiers in Aging. https://pubmed.ncbi.nlm.nih.gov/41704678/
- Berven, H., et al. (2026). Pharmacokinetics of NR or NMN administration in humans: blood and cerebral NAD+ dynamics. iScience. https://pubmed.ncbi.nlm.nih.gov/41858901/
- Bagga, P., et al. (2019/2020). Sensitivity of ³¹P MRS to changes in brain NAD+ concentration with age. Magnetic Resonance in Medicine. https://pubmed.ncbi.nlm.nih.gov/31502710/
- Schwarzmann, L., Pliquett, R. U., Simm, A., & Bartling, B. (2021). Sex-related differences in human plasma NAD+/NADH levels depend on age. Bioscience Reports, 41(1), BSR20200340. https://pubmed.ncbi.nlm.nih.gov/33393613/